Novartis strengthens oral BTK franchise as Rhapsido expands beyond chronic spontaneous urticaria

Novartis has expanded the commercial runway for Rhapsido after the FDA approved the oral BTK inhibitor as the first treatment specifically indicated for symptomatic dermographism in adults whose disease remains uncontrolled by H1 antihistamines. The new label gives Rhapsido access to another chronic-hives population only months after its launch in chronic spontaneous urticaria, where the medicine generated $64 million in second-quarter sales and Novartis described early U.S. uptake as strong. Symptomatic dermographism is a smaller opportunity than some of remibrutinib’s other development programs, but the approval reinforces Novartis’ strategy of turning one molecule into a broader immune-mediated disease franchise. Investors appear to be viewing the expansion as another positive pipeline milestone rather than a company-changing event, with Novartis ADRs trading about 2% higher around $143.50 during the current session.

The commercial importance extends beyond the immediate dermographism market. Remibrutinib has already delivered positive Phase III results in relapsing multiple sclerosis and is being studied across food allergy, hidradenitis suppurativa and additional immune-mediated conditions, giving Novartis what management has described as a potential “pipeline-in-a-pill.” The latest FDA decision therefore adds another revenue opportunity while strengthening the safety and regulatory track record of a molecule that could eventually compete in markets far larger than chronic urticaria.

Symptomatic dermographism approval broadens the addressable market beyond Rhapsido’s first hives indication

Symptomatic dermographism is the most common form of chronic inducible urticaria and causes raised, itchy welts after ordinary friction, scratching or pressure on the skin. For patients whose symptoms remain uncontrolled by antihistamines, treatment options have historically been limited and frequently borrowed from therapies used in other forms of chronic hives rather than medicines developed specifically for the condition.

Rhapsido changes that competitive landscape by becoming the first FDA-approved therapy specifically for adults with symptomatic dermographism inadequately controlled by H1 antihistamines. Novartis says chronic spontaneous urticaria and symptomatic dermographism together account for more than 90% of adults living with chronic hives, meaning the second indication expands Rhapsido across much of the disease spectrum rather than adding an isolated niche label.

That broader positioning could improve commercial efficiency because the same allergists, dermatologists and other specialists treating chronic spontaneous urticaria may also manage symptomatic dermographism. Novartis can therefore expand use through an existing physician network without building an entirely separate sales infrastructure for the new indication.

The company also benefits from an administration advantage. Rhapsido is taken orally and does not require routine laboratory monitoring, potentially simplifying chronic treatment compared with therapies that require injections or more intensive safety surveillance. That convenience will matter most if physicians believe its efficacy justifies moving patients beyond antihistamines.

Phase III response supports the label expansion but also shows the limits of complete symptom control

The Phase III RemIND study gives Novartis a conventionally positive regulatory dataset, but the magnitude of complete response provides important context for the commercial story. At Week 12, 29.3% of adults receiving Rhapsido achieved complete hive resolution compared with 14.0% receiving placebo, while treatment effects were detectable as early as Week 2.

The result means Rhapsido roughly doubled the complete-response rate, but it also means about seven in 10 treated patients did not become entirely hive-free during the 12-week controlled period. Commercial messaging will therefore need to balance the first-in-indication status against the reality that symptomatic dermographism remains difficult to eliminate completely.

Partial improvement could still carry meaningful value, particularly for patients whose symptoms are triggered repeatedly by unavoidable everyday contact. Additional data covering itch, quality of life, durability and broader disease control may influence whether physicians move quickly from antihistamines to Rhapsido or reserve it for patients with more persistent disease.

The safety profile creates fewer obvious barriers to adoption. Novartis reported that safety in symptomatic dermographism was consistent with its chronic spontaneous urticaria experience, with no new signal requiring routine laboratory monitoring. Common adverse events across the broader Rhapsido program include nasopharyngitis, headache, nausea, abdominal pain and bleeding events.

That consistency matters because chronic urticaria treatment may continue for extended periods. Building a large outpatient franchise requires not only efficacy but also enough long-term tolerability that clinicians are comfortable prescribing the therapy broadly outside specialized trial settings.

Early $64 million Rhapsido sales give Novartis evidence that an oral BTK hives treatment can gain traction

Rhapsido is still early in its launch cycle, but the initial commercial performance provides evidence that physicians and patients are adopting the oral BTK strategy. Novartis reported $64 million in second-quarter Rhapsido sales and said the U.S. launch in chronic spontaneous urticaria was benefiting from increasing insurance coverage and a free-drug program designed to facilitate patient access.

That contribution remains small relative to Novartis’ largest brands. The company generated $14.4 billion in total second-quarter sales, while Kisqali, Kesimpta and Cosentyx each produced more than $1 billion during the period. Rhapsido nevertheless represents one of the company’s newest growth launches and could become more meaningful as additional indications accumulate.

Symptomatic dermographism could help accelerate that uptake by increasing the number of patients who qualify for treatment and giving specialists a single oral therapy across two major chronic-hives populations. The label expansion may also improve payer negotiations because insurers can evaluate Rhapsido as a broader urticaria product rather than one limited to chronic spontaneous disease.

Novartis still has to prove that early prescription momentum becomes durable revenue growth. Free-drug programs can help establish patient access during a launch but do not necessarily translate directly into paid prescriptions, while insurers may impose prior-authorization requirements before allowing use beyond antihistamines.

That makes future quarterly Rhapsido sales increasingly important. The symptomatic dermographism approval provides a larger market, but the pace at which new patients convert into reimbursed therapy will determine how quickly the franchise becomes financially meaningful.

Multiple sclerosis could ultimately dwarf the commercial value of the chronic-hives franchise

The largest upside attached to remibrutinib may have little to do with dermatology or allergy. Novartis recently reported positive Phase III REMODEL-1 and REMODEL-2 trials in relapsing multiple sclerosis, where remibrutinib significantly reduced annualized relapse rates compared with teriflunomide and achieved superiority across key MRI endpoints.

The company also reported a clinically meaningful delay in disability progression and said the safety profile remained consistent with more than 4,500 participants exposed across the broader development program. Importantly, Novartis again reported no liver-safety signal meeting Hy’s Law criteria, a potentially useful differentiator within the competitive BTK inhibitor field.

Multiple sclerosis represents a much larger commercial market than symptomatic dermographism and could reposition remibrutinib from a growing immunology product into one of Novartis’ major neuroscience franchises. The company already sells Kesimpta, which generated $1.42 billion in second-quarter sales and grew 32% at constant currencies, giving Novartis substantial commercial infrastructure and physician relationships in MS.

Remibrutinib could eventually complement that franchise with an oral treatment, potentially giving Novartis options across different patient preferences and disease settings. The company is also running a Phase III study in secondary progressive multiple sclerosis, further extending the molecule’s potential neuroscience reach.

Those opportunities remain investigational and will depend on regulatory submissions, detailed efficacy comparisons and long-term safety. The positive Phase III data nevertheless make the symptomatic dermographism approval strategically more interesting because every successful immune indication adds exposure and safety experience around a medicine Novartis hopes to deploy much more broadly.

Food allergy and hidradenitis programs add more optionality to the remibrutinib franchise

Novartis is also testing remibrutinib across other immune-mediated diseases, giving the molecule several additional routes to commercial expansion. A Phase III food-allergy study is recruiting adolescents and adults with peanut, milk or egg allergy and is expected to enroll about 576 participants.

The company is simultaneously running Phase III development in moderate-to-severe hidradenitis suppurativa, including a long-term extension program assessing continued efficacy and safety. These programs remain substantially earlier from a regulatory perspective than the approved urticaria indications, but successful readouts would broaden the number of specialties prescribing the same oral molecule.

That “pipeline-in-a-pill” model can be financially attractive because a company can leverage much of the same manufacturing, safety database and drug-development knowledge across several diseases. Each additional indication also reduces dependence on any single market and can extend the commercial lifetime of the molecule.

The risk is that mechanistic promise does not guarantee consistent efficacy across unrelated immune diseases. Novartis must still prove remibrutinib separately in every indication, and unsuccessful Phase III programs could limit the breadth of the franchise despite the drug’s success in urticaria.

For now, the FDA’s symptomatic dermographism approval provides another tangible validation point. Rhapsido has progressed from one chronic-hives indication into a broader urticaria franchise while simultaneously producing late-stage evidence in multiple sclerosis and advancing through additional immunology trials.

Novartis shares rise as investors weigh the approval within a much larger growth portfolio

Novartis ADRs were trading around $143.50 during the current session, roughly 2% above the previous close of $140.79. The company has a market capitalization of about $274 billion, making the incremental commercial contribution from symptomatic dermographism relatively small compared with the value of its established oncology, cardiovascular, immunology and neuroscience businesses.

That scale explains why the Rhapsido approval alone is unlikely to determine near-term investor sentiment. Novartis’ second-quarter growth was driven by established priority brands including Kisqali, Kesimpta, Scemblix, Pluvicto and Leqvio, while management continues to invest heavily in new launches and pipeline assets.

Rhapsido becomes more consequential when investors look beyond the new hives label. The product has already generated $64 million in a quarter, now addresses another chronic-hives population and has positive Phase III multiple-sclerosis data behind the same active molecule.

The latest approval therefore strengthens an emerging multi-indication asset rather than creating a standalone blockbuster story. Symptomatic dermographism may provide incremental revenue and expand prescriber familiarity, but the larger valuation opportunity will depend on whether Novartis can convert remibrutinib’s positive MS trials and additional immune-disease programs into approvals.

If that strategy succeeds, Rhapsido could evolve from a specialized urticaria launch into a much broader growth franchise. The FDA’s latest decision is another step in that direction, but the scale of the opportunity will ultimately be determined well beyond the dermatology clinic.

Key takeaways from Novartis’ Rhapsido label expansion and remibrutinib growth strategy

• FDA approval makes Rhapsido the first treatment specifically indicated for symptomatic dermographism uncontrolled by H1 antihistamines.
• Complete hive resolution reached 29.3% with Rhapsido versus 14.0% with placebo in the Phase III RemIND trial.
• Rhapsido now covers chronic spontaneous urticaria and symptomatic dermographism, the two major chronic-hives populations highlighted by Novartis.
• The oral therapy requires no routine laboratory monitoring, supporting its potential use as a long-term outpatient treatment.
• Rhapsido generated $64 million in second-quarter sales as its initial U.S. chronic spontaneous urticaria launch gained traction.
• Novartis already has substantial commercial infrastructure across immunology and specialty medicine that can support the label expansion.
• Positive Phase III multiple-sclerosis results could create a much larger commercial opportunity for remibrutinib than chronic urticaria alone.
• Phase III programs in food allergy and hidradenitis suppurativa provide additional long-term expansion opportunities.
• Novartis ADRs were trading about 2% higher during the session, although the company’s $270 billion-plus valuation means the new indication is only one part of a much broader growth portfolio.